Table 1.
Sample | Total number | Median age (range) | Gender (male/female) |
---|---|---|---|
Healthy donors | 18 | 47.5 (35–63) | 9/9 |
Pleomorphic adenoma | 7 | 43.9 (18–60) | 1/6 |
Thyroid papillary adenocarcinoma | 9 | 56.3 (35–67) | 2/7 |
Head and neck squamous cell carcinoma | 32 | 67.0 (34–83) | 26/6 |
Age | Gender | Primary of HNSCC | TNM | Stage |
---|---|---|---|---|
34 | F | Tongue | T1N0M0 | I |
67 | M | Tongue | T1N0M0 | I |
39 | M | Tongue | T4aN2cM0 | IV |
77 | M | Tongue | T2N2bM0 | IV |
64 | M | Tongue | T2N2bM0 | IV |
77 | M | Tongue | T2N2bM0 | IV |
64 | F | Oral floor | T4N2M0 | IV |
74 | M | Larynx | T1aN0M0 | I |
81 | M | Larynx | T2N0M0 | II |
75 | M | Larynx | T2N1M0 | III |
78 | M | Larynx | T3N0M0 | III |
72 | M | Larynx | T3N0M0 | III |
51 | M | Larynx | T4aN2cM0 | IV |
65 | M | Maxillary sinus | T3N0M0 | III |
60 | M | Maxillary sinus | T4aN0M0 | IV |
40 | F | Maxillary sinus | T4aN0M0 | IV |
71 | M | Maxillary sinus | T4bN0M0 | IV |
74 | M | Maxillary sinus | T4bN2bM0 | IV |
75 | M | Maxillary sinus | T3N1M0 | III |
56 | M | Oropharynx | T1N2bM0 | IV |
63 | F | Oropharynx | T2N2bM0 | IV |
77 | M | Oropharynx | T2N2bM0 | IV |
67 | F | Oropharynx | T4N3M0 | IV |
82 | M | Oropharynx | T4N2M1 | IV |
66 | M | Hypopharynx | T1N0M0 | I |
71 | M | Hypopharynx | T2N1M0 | III |
57 | M | Hypopharynx | T1N3M0 | IV |
68 | M | Hypopharynx | T4aN2bM0 | IV |
69 | M | Hypopharynx | T4aN2cM1 | IV |
74 | F | Hypopharynx | T4aN0M0 | IV |
75 | M | Hypopharynx | T4N2cM0 | IV |
83 | M | Hypopharynx | T4bN2bM0 | IV |